Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia
Ondine Walter,
Agnès Ribes,
Johanne Germain,
Jean-Baptiste Rieu,
Thibaut Comont,
Albertine Plat,
Brigitte Rivière,
Laureline Deluche,
Lucrecia Delarue,
Isabelle LeGoff,
Monique Greze,
Béatrice Dubourdieu,
Odile Rauzy,
Veronique Mansat-De Mas,
Guillaume Moulis,
the CARMEN investigators group.
Affiliations
Ondine Walter
Toulouse University Hospital
Agnès Ribes
Laboratory of Hematology, Toulouse University Hospital
Johanne Germain
CIC 1436, team PEPSS, Toulouse University Hospital
Jean-Baptiste Rieu
Laboratory of Hematology, Toulouse University Hospital
Thibaut Comont
Toulouse University Hospital
Albertine Plat
Laboratory of Hematology, Tarbes Hospital, Tarbes, France
Brigitte Rivière
Castres-Mazamet Hospital
Laureline Deluche
Laboratory of Hematology, Montauban Hospital
Lucrecia Delarue
Laboratory of Hematology, Cahors Hospital
Isabelle LeGoff
Laboratory of Hematology, Pamiers Hospital
Monique Greze
Laboratory of Hematology, Albi Hospital
Béatrice Dubourdieu
Laboratory of Hematology, Rodez Hospital
Odile Rauzy
Toulouse University Hospital
Veronique Mansat-De Mas
Laboratory of Hematology, Toulouse University Hospital
Impaired platelet production is a mechanism of immune thrombocytopenia (ITP). Morphological abnormalities of megakaryocytes (MKs) are sometimes observed in this disease. Two studies have suggested an association between MK abnormalities and response to corticosteroids in primary ITP, but none have investigated this association for thrombopoietin-receptor agonists (TPO-RAs). This was the aim of this study. The source of population was the French CARMEN registry with prospective follow-up of adult patients with incident ITP. We included patients with primary ITP, treated by TPO-RA and with a bone marrow smear before initiating TPO-RA. MK abnormalities were categorized by the presence of dysplasia and by the stage of maturation. Among 451 patients screened, 38 were included in the analysis. There was no difference in the median percentage of dysplastic MKs between responders to TPO-RA (4.0%, 95% confidence interval – CI: 2.3–6.4) and non-responders (4.5%, 95% CI: 0.7–7.1). There was a slightly higher proportion of granular MKs (4.5%, 95% CI: 3–6) and basophilic MKs (30.1%, 95% CI: 21.9–39.1) in non-responders compared to responders (granular: 2.0%, 95% CI: 0–4.1; basophilic: 21.3%, 95% CI: 11.4–40.7). In conclusion, MK abnormalities were not associated with response achievement in ITP patients treated with TPO-RA in this series of 38 patients.